Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Stoke Therapeutics's Enterprise Value is $1,651.91 Mil.
Stoke Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-185.25 Mil. Therefore, Stoke Therapeutics's EV-to-EBIT ratio for today is -8.92.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Stoke Therapeutics's Enterprise Value is $1,651.91 Mil.
Stoke Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-183.52 Mil. Therefore, Stoke Therapeutics's EV-to-EBITDA ratio for today is -9.00.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Stoke Therapeutics's Enterprise Value is $1,651.91 Mil.
Stoke Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $32.08 Mil. Therefore, Stoke Therapeutics's EV-to-Revenue ratio for today is 51.49.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Stoke Therapeutics (NAS:STOK) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Stoke Therapeutics's current Enterprise Value is $1,651.91 Mil.
Stoke Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-185.25 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Stoke Therapeutics's current Enterprise Value is $1,651.91 Mil.
Stoke Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-183.52 Mil.
Stoke Therapeutics's current Enterprise Value is $1,651.91 Mil.
Stoke Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $32.08 Mil.
Stoke Therapeutics's current Enterprise Value is $1,651.91 Mil.
Stoke Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-146.82 Mil.
Stoke Therapeutics's current Enterprise Value is $1,651.91 Mil.
Stoke Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-147.70 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stoke Therapeutics Enterprise Value Related Terms
Stoke Therapeutics Enterprise Value Historical Data
* Premium members only.
The historical data trend for Stoke Therapeutics's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STOK vs SION, RXRX, VRDN: Enterprise Value Comparison
For the Biotechnology subindustry, Stoke Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stoke Therapeutics Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stoke Therapeutics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Stoke Therapeutics's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Stoke Therapeutics's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of $1,651.91 Mil mean?
Stoke Therapeutics (STOK) has a Enterprise Value of $1,651.91 Mil as of Jun. 27, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Stoke Therapeutics and its competitors.
Is Stoke Therapeutics' Enterprise Value too high?
Stoke Therapeutics' current Enterprise Value is $1,651.91 Mil. Overall, Stoke Therapeutics has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stoke Therapeutics' Enterprise Value compare to SION and RXRX?
Stoke Therapeutics' Enterprise Value of $1,651.91 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Stoke Therapeutics and its competitors. Stoke Therapeutics's current Enterprise Value is $1,651.91 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stoke Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Stoke Therapeutics (STOK) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.16, compared to a current price of $31.90 — trading 214% above its estimated fair value. The current Enterprise Value is $1,651.91 Mil. Stoke Therapeutics' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Stoke Therapeutics (STOK), the current Enterprise Value is $1,651.91 Mil as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stoke Therapeutics (STOK) Overvalued in 2026?
Based on GuruFocus' analysis, Stoke Therapeutics stock appears to be overvalued.
The current stock price of $31.90 is trading 214% above its estimated GF Value™ of $10.16.
GuruFocus considers Stoke Therapeutics to be Significantly Overvalued.
Key valuation signals for STOK:
Enterprise Value: $1,651.91 Mil
GF Value™: $10.16 vs. price of $31.90 (214% above fair value)
No single metric tells the full story. See the STOK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
45GF Score
Get the complete analysis for STOK
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STOK has been successfully added to your 
